Longeveron (LGVN) Income from Continuing Operations (2020 - 2026)
Longeveron (LGVN) posted quarterly Income from Continuing Operations of 5545000.0 for Q1 2026, up 14.64% year-over-year from 4836890.02 in Q1 2025, and up 11.31% quarter-over-quarter from 6252000.0 in Q4 2025.
Longeveron (LGVN) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Longeveron's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 5545000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 14.64% year-over-year to 5545000.0; the TTM figure through Mar 2026 stood at 27384000.0 (down 35.82% YoY), while the FY2025 annual figure was 24340000.0, up 29.52% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 5545000.0, up from 6252000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3547000.0 in Q2 2024, with the low at 42716000.0 in Q1 2023.
- The 5-year median for Income from Continuing Operations is 5411000.0 (2022), against an average of 7708294.12.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 942.87% in 2023, then soared 89.9% in 2024.
- Longeveron's Income from Continuing Operations stood at 5229000.0 in 2022, then decreased by 4.63% to 5471000.0 in 2023, then grew by 4.11% to 5246000.0 in 2024, then dropped by 19.18% to 6252000.0 in 2025, then increased by 11.31% to 5545000.0 in 2026.
- Business Quant data shows LGVN's Income from Continuing Operations at 5545000.0 in Q1 2026, 6252000.0 in Q4 2025, and 8778000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -6.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.50 Mn |
| Mar 31, 2026 | -5.55 Mn |
| Dec 31, 2025 | -6.25 Mn |
| Sep 30, 2025 | -8.78 Mn |
| Jun 30, 2025 | -6.81 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -5.25 Mn |
| Sep 30, 2024 | -4.87 Mn |
| Jun 30, 2024 | -3.55 Mn |
| Mar 31, 2024 | -4.31 Mn |
| Dec 31, 2023 | -5.47 Mn |
| Sep 30, 2023 | -5.39 Mn |
| Jun 30, 2023 | -5.95 Mn |
| Mar 31, 2023 | -42.72 Mn |
| Dec 31, 2022 | -5.23 Mn |
| Sep 30, 2022 | -5.41 Mn |
| Jun 30, 2022 | -4.92 Mn |
| Mar 31, 2022 | -4.10 Mn |
| Dec 31, 2021 | 44.90 Mn |
| Sep 30, 2021 | -22.91 Mn |